What happened with PHIO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Phio Pharmaceuticals Corp. is a clinical-stage drug developer working on treatments designed to stop tumors from evading the immune system. Its proprietary INTASYL technology uses chemically modified small interfering RNA to silence genes involved in that evasion. The business depends heavily on this still-unproven platform and the drug candidates built from it.
Phio has not generated operating revenue; securities sales have been its main source of funding. It relies on outside organizations to conduct clinical trials and on contract manufacturers to supply drug materials, since it has no manufacturing capability of its own. Turning its candidates into commercial products requires successful studies and regulatory approval. Continued development also depends on raising additional capital.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Xilio Therapeutics, Inc. offers a competing approach to Phio Pharmaceuticals Corp.’s effort to activate immunity against tumors: biologic drugs activated within tumors rather than RNA that silences genes used to evade immune attack. Watch its Phase 2 trial of efarindodekin alfa in advanced solid tumors and the data package it expects to deliver to licensing partner Gilead in the first half of 2027.
Pliant Therapeutics, Inc. competes with Phio Pharmaceuticals Corp.’s effort to counter tumor immune evasion by developing a drug for solid tumors resistant to treatments that release the brakes on immune cells, known as immune checkpoint inhibitors. Watch PLN-101095, its oral drug designed to block two integrin proteins, for progress in that resistant-tumor patient group.
Kairos Pharma, Ltd. and Phio Pharmaceuticals Corp. are developing competing cancer therapies intended to strengthen immune responses against tumors, with Phio using gene-silencing RNA. Watch Kairos’s candidates aimed at immune responses and treatment resistance across prostate, lung, breast and brain cancers; none of its candidates had regulatory approval as of its 2025 Annual Report.
Pliant Therapeutics, Inc. earningsPLRX
Pliant Therapeutics’ report will show how its oral drug PLN-101095 is progressing in solid tumors resistant to immune checkpoint inhibitors, a treatment need its program shares with Phio.
Look for trial progress of PLN-101095 in checkpoint-inhibitor-resistant tumors, keeping its oral integrin-blocking approach distinct from Phio’s intratumoral PH-762. Clear progress would show another approach to the same unmet treatment need moving forward, making competition for Phio more concrete. Limited progress would mean less pressure from this program, not proof that Phio’s treatment works.
Phio Pharmaceuticals Corp. earningsThis company
Phio Pharmaceuticals has no product revenue, so its report will show how PH-762’s clinical development is progressing and how much cash that work is using.
Look for interpretable progress from the fully enrolled, 22-patient Phase 1b trial of PH-762, and read research spending alongside the cash balance. Clear progress with cash use still controlled would show Phio advancing its gene-silencing treatment while preserving room to develop it further. Unclear findings or delays alongside faster cash use would leave the treatment unproven and increase pressure to raise funds or cut research.
